PD-1/VEGF Bispecifics Development and Regulatory Challenges

This technical report examines the development and regulatory landscape of PD-1/VEGF bispecific antibodies, particularly focusing on ivonescimab (AK112) and its transition from a China-centric success to a global context. The report outlines the rapid ascent of ivonescimab, highlighting its approvals in China and the compelling clinical data that contributed to its initial success. However, it also details the challenges faced as the program moves into the more stringent FDA regulatory environment, where the divergence between perceived momentum and actual evidence becomes apparent. The report discusses the implications of the global HARMONi Phase 3 trial, where primary endpoints of progression-free survival (PFS) were met, but overall survival (OS) did not achieve statistical significance. It concludes by addressing the elevated late-stage risks associated with PD-1/VEGF programs and emphasizes the need for cautious capital allocation and strategic planning in light of these challenges.